DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women]

Author(s): Yuan T, Li XL, Zhang CQ, Shi HP, Zeng BF

Affiliation(s): Orthopedic Department, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China. terrence_yuan@yahoo.com.cn

Publication date & source: 2009-06-16, Zhonghua Yi Xue Za Zhi., 89(23):1620-2.

Publication type: English Abstract; Meta-Analysis

OBJECTIVE: To study the efficacy of alendronate to prevent hip fracture risk of postmenopausal women. METHODS: Randomized controlled trials in postmenopausal women receiving alendronate or placebo for preventing hip fractures rate were searched from Medline, EMBASE, Cochrane Trial Registry and China Biological Medicine database between January 1980 to December 2007. Key words included hip fractures, alendronate, postmenopausal and placebo-controlled. Language was limited in English and Chinese. The software Revman 4.2 was used to perform meta-analysis. RESULTS: Six trials, which included 8610 postmenopausal women, met all our inclusion criteria Meta-analysis showed that alendronate can decrease hip fracture rate (OR = 0.51, 95% CI: 0.34, 0.77). CONCLUSION: Alendronate can reduce significantly hip fracture rate in postmenopausal women.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017